Posted by Michael Wonder on 21 Jan 2023
MedPacto receives US FDA fast track designation for vactosertib for the treatment of metastatic osteosarcoma
17 January 2023 - MedPacto announced that the US FDA has granted fast track designation to vactosertib as a monotherapy treatment for relapsed/refractory metastatic osteosarcoma.
MedPacto received IND approval for a Phase 1/2 clinical metastatic osteosarcoma trial in August 2022.
